Vaneltix Pharma is a specialty pharmaceutical company dedicated to addressing significant unmet medical needs in urology and women's health care, particularly focusing on conditions such as Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Their flagship product, Alenura™, is a proprietary combination of heparin and alkalinized lidocaine designed to provide immediate relief from acute pelvic pain associated with IC/BPS. This innovative approach aims to improve the quality of life for millions of individuals suffering from urological disorders, with additional products in development that include an enhanced formulation of the existing IC/BPS drug Elmiron and regenerative therapies targeting bladder wall lining.

The company employs a strategic development pathway, utilizing the FDA's 505(b)(2) regulatory framework to expedite the approval of repurposed therapeutic products. Vaneltix's commitment to clinical research is underscored by their recent announcement of new clinical trials aimed at further validating their treatment options. Collaborations, such as the joint development agreement with Hyloris Pharmaceuticals, highlight Vaneltix's proactive approach to securing funding and expertise to advance their product candidates toward commercialization, ultimately aiming to meet the needs of the over six million individuals affected by bladder pain in the U.S.

United States

We Specialize in Urology and Women’s Health Care.Pain, urgency, frequency. Every day, urologic disorders continue to affect the lives of people all around us.

Vaneltix is focused on providing immediate relief for patients suffering from Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), a disease of the lower urinary tract that predominantly affects women.

Vaneltix Pharma

Company Details